Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer

Xiaobin Hou; Jiaxin Wen; Zhipeng Ren; Guoliang Zhang

doi:10.18632/oncotarget.16721

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer

Xiaobin Hou, Jiaxin Wen, Zhipeng Ren and Guoliang Zhang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:43571-43578. https://doi.org/10.18632/oncotarget.16721

Metrics: PDF 4634 views | HTML 4140 views | ?

Abstract

Xiaobin Hou1,*, Jiaxin Wen1,*, Zhipeng Ren1 and Guoliang Zhang2

1 Department of Thoracic Surgery, PLA General Hospital, Beijing, China

2 Medical Science Weekly, Beijing, China

* These authors have contributed to this work equally

Correspondence to:

Guoliang Zhang, email:

Keywords: esophageal cancer; lncRNAs; miRNAs; biomarker; therapeutic target

Received: November 11, 2016 Accepted: January 27, 2017 Published: March 30, 2017

Abstract

Esophageal cancer is one of the most common gastrointestinal malignant diseases and there is still no effective treatment. The incidence of esophageal cancer in the world is relatively high and on the increase year by year. Thus, the elaboration on the carcinogenesis of esophageal cancer and the identification of new biomarkers and therapeutic targets is quite beneficial to optimizing the current therapeutic regimen for treating such deadly disease. More and more evidence has shown that non-coding RNAs play an important role in the development and progression of multiple human cancers, including esophageal cancer. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two functional kinds of non-coding RNAs that have been well investigated. They exert tumor suppressive or promoting effect by specifically regulating the expression of certain downstream target genes, which is tumor specific. It is also proved that miRNAs and lncRNAs level in tissue and plasma from esophageal cancer patients are closely correlated with the survival and disease progression, which could be used as a prognostic factor and therapeutic target for esophageal cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16721

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer

Abstract